Clonazepam

Clonazepam is indicated as monotherapy or as an adjunct in the treatment of Lennox-Gastaut syndrome (petit mal variant), akinetic, and myoclonic seizures. Furthermore, clonazepam may also be of some value in patients with absence spells (petit mal) who have failed to respond to succinimides. Additionally, clonazepam is also indicated for the treatment of panic disorder, with or without agoraphobia, as defined in the DSM-V. Alternatively, some regional prescribing information note that clonazepam is indicated for all clinical forms of epileptic disease and seizures in adults, especially absence seizures (petit mal) including atypical absence; primary or secondarily generalised tonic-clonic (grand mal), tonic or clonic seizures; partial (focal) seizures with elementary or complex symptomatology; various forms of myoclonic seizures, myoclonus and associated abnormal movements. Such regional label data also has clonazepam indicated for most types of epilepsy in infants and children, especially absences (petit mal), myoclonic seizures and tonic-clonic fits, whether due to primary generalized epilepsy or to secondary generalization of partial epilepsy.

• Akinetic seizures
• Burning Mouth Syndrome
• Essential Tremor
• Gilles de la Tourette's Syndrome
• Lennox-Gastaut Syndrome
• Mixed manic depressive episode
• Panic Disorder
• Rapid Eye Movement Sleep Disorder
• Restless Legs Syndrome (RLS)
• Tardive Dyskinesia (TD)
• Acute Manic episode
• Myoclonic seizures
• Refractory absence Seizures